BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 34919247)

  • 1. A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
    Fouda A; Abdelaziz AE; Hussien M; Ali AA; Abdelkawy KS; Elbarbry F
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7449-7459. PubMed ID: 34919247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.
    Dufour JF; Oneta CM; Gonvers JJ; Bihl F; Cerny A; Cereda JM; Zala JF; Helbling B; Steuerwald M; Zimmermann A;
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1537-43. PubMed ID: 17162245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial.
    Van Wagner LB; Koppe SW; Brunt EM; Gottstein J; Gardikiotes K; Green RM; Rinella ME
    Ann Hepatol; 2011; 10(3):277-86. PubMed ID: 21677329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
    Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
    Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
    Ratziu V; de Ledinghen V; Oberti F; Mathurin P; Wartelle-Bladou C; Renou C; Sogni P; Maynard M; Larrey D; Serfaty L; Bonnefont-Rousselot D; Bastard JP; Rivière M; Spénard J;
    J Hepatol; 2011 May; 54(5):1011-9. PubMed ID: 21145828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review.
    Xiang Z; Chen YP; Ma KF; Ye YF; Zheng L; Yang YD; Li YM; Jin X
    BMC Gastroenterol; 2013 Sep; 13():140. PubMed ID: 24053454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of NASH with ursodeoxycholic acid: cons.
    Liechti F; Dufour JF
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S46-52. PubMed ID: 23141894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis.
    Lin X; Mai M; He T; Huang H; Zhang P; Xia E; Guo H
    Expert Rev Gastroenterol Hepatol; 2022 Jun; 16(6):537-545. PubMed ID: 35617696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
    Georgescu EF; Georgescu M
    J Gastrointestin Liver Dis; 2007 Mar; 16(1):39-46. PubMed ID: 17410287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis.
    Ozel Coskun BD; Yucesoy M; Gursoy S; Baskol M; Yurci A; Yagbasan A; Doğan S; Baskol G
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):142-9. PubMed ID: 25533429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
    Lee SH; Cheon GJ; Kim HS; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS
    Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
    Parikh P; Ingle M; Patel J; Bhate P; Pandey V; Sawant P
    Saudi J Gastroenterol; 2016; 22(3):192-7. PubMed ID: 27184636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
    Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
    Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report].
    Bernal-Reyes R; Escudero RB
    Rev Gastroenterol Mex; 2002; 67(2):70-5. PubMed ID: 12214337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
    Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of combining pentoxiphylline and vitamin E versus vitamin E alone in non-alcoholic steatohepatitis- A randomized pilot study.
    Kedarisetty CK; Bhardwaj A; Kumar G; Rastogi A; Bihari C; Kumar M; Sarin SK
    Indian J Gastroenterol; 2021 Feb; 40(1):41-49. PubMed ID: 33772456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
    World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S; Rustgi VK
    Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMPARATIVE ANALYSIS OF EFFICIENCY OF URSODEOXYCHOLIC ACID AND COMBINATION OF VITAMIN E AND VITAMIN C IN TREATMENT OF NON-DIABETIC NONALCOHOLIC STEATOHEPATITIS.
    Barbakadze G; Khachidze T; Sulaberidze G; Burnadze K; Jebashvili M
    Georgian Med News; 2019 Mar; (288):81-85. PubMed ID: 31101782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial.
    Traussnigg S; Schattenberg JM; Demir M; Wiegand J; Geier A; Teuber G; Hofmann WP; Kremer AE; Spreda F; Kluwe J; Petersen J; Boettler T; Rainer F; Halilbasic E; Greinwald R; Pröls M; Manns MP; Fickert P; Trauner M;
    Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):781-793. PubMed ID: 31345778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.